
- /
- Supported exchanges
- / US
- / SMMT.NASDAQ
Summit Therapeutics PLC (SMMT NASDAQ) stock market data APIs
Summit Therapeutics PLC Financial Data Overview
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Summit Therapeutics PLC data using free add-ons & libraries
Get Summit Therapeutics PLC Fundamental Data
Summit Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -235 366 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-29
- EPS/Forecast: -0.0682
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Summit Therapeutics PLC News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such inv...


Why Summit Therapeutics Stock Tanked Today
An analyst's downbeat new take on Summit Therapeutics(NASDAQ: SMMT) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors absor...

Why Summit Therapeutics Stock Tanked Today
Key Points An analyst launched coverage of the biotech stock. The company might have wished she hadn't, though. 10 stocks we like better than Summit Therapeutics › An analyst's downbeat new take o...

Merck rival Summit draws a rare sell-equivalent rating
[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Shares of Summit Therapeutics (NASDAQ:SMMT [https://seekingalpha.com/symbol/SMMT]) ended four straight sessions of gains on Wednes...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.